Table 3 Summary of treatment-emergent adverse events in all treated Chinese participants
TEAE, n (%) | Rimegepant 75 mg n = 538 | Placebo n = 537 |
|---|---|---|
Any TEAE | 82 (15.2) | 88 (16.4) |
Serious TEAE | 1 (0.2)a | 2 (0.4) |
Most common TEAEsb | ||
Protein urine present | 8 (1.5) | 7 (1.3) |
Nausea | 6 (1.1) | 14 (2.6) |
Urinary tract infection | 5 (0.9) | 8 (1.5) |
Blood creatine phosphokinase increased | 5 (0.9) | 3 (0.6) |
Proteinuria | 4 (0.7) | 1 (0.2) |
Photophobia | 4 (0.7) | 3 (0.6) |
Upper respiratory tract infection | 3 (0.6) | 4 (0.7) |
Blood urine present | 3 (0.6) | 2 (0.4) |
Blood glucose increased | 3 (0.6) | 1 (0.2) |
Urine leukocyte esterase positive | 3 (0.6) | 1 (0.2) |
Study drug-related | ||
Any TEAE | 45 (8.4) | 43 (8.0) |
Serious TEAE | 0 | 1 (0.2) |